Reporter brief
RCT of everolimus and exercise for postmenopausal bone loss shows no reported effect sizes.
What happened
This 24-week randomized controlled trial enrolled 136 postmenopausal women (aged 45-60) assigned to control, exercise training, everolimus (5 mg weekly), or combined treatment. The primary outcome was percentage change in bone formation marker P1NP at week 24, with secondary outcomes including bone resorption marker CTX, bone mineral density, bone structure, muscle function, and postural balance. The study does not report the effect sizes or results for any outcome.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Healthy postmenopausal women aged 45-60 years with T-score >-3 and no history of hip, Colles' or symptomatic vertebral fractures within the last 6 months
- Design
- Rct
- Sample
- 136
- Journal
- Odense University Hospital
- Published
- Apr 7, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.